Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: 25 January, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 1.08 billion |
|
Revenue forecast in 2030 |
US$ 2.76 billion |
|
Growth Rate |
CAGR of 11% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Historical Years |
2020 |
|
Segments covered |
Drug class, Distribution channel and Region |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market was pegged at US$ 1.08 billion in 2021, and is expected to witness a CAGR of 11% during the forecast period.
Market Fundamentals
The most frequent type of polycystic kidney disease (PKD) is autosomal dominant polycystic kidney disease (ADPKD). ADPKD affects one out of every 400 to 1,000 persons and is the most common kidney illness handed down via via lineage. The term "autosomal dominant" refers to the fact that the PKD gene mutation or defect, can be inherited from only one parent. Autosomal dominant polycystic kidney disease is caused by two distinct gene mutations, according to researchers. A majority of patients with autosomal dominant polycystic kidney disease have PKD1 gene deficiencies, while one in every six or one in every seven people with ADPKD has a faulty PKD2 gene. Autosomal dominant polycystic kidney disease is caused by a genetic flaw that impairs the normal growth of some kidney cells, resulting in cyst formation. Autosomal dominant polycystic kidney disease is known to be caused by mutations in one of two distinct genes - PKD1, which accounts for 85% of instances, and PKD2, which accounts for 15% of cases, are the afflicted genes. Both kinds have the same symptoms, however PKD1 associated variant is more severe. If one of the parents carries the defective PKD1 or PKD2 gene, the child has a 50% chance of getting autosomal dominant polycystic kidney disease. In Autosomal dominant polycystic kidney disease (ADPKD), the genotype-phenotype connection is not fully known. The condition is associated with a wide range of phenotypes, ranging from new-borns with enormous cystic kidneys to those whose renal function remains acceptable well into old age. The identification of the afflicted locus (PKD1 vs PKD2 mutation), the allelic variant (truncating, non-truncating, or hylomorphic), the timing of gene inactivation, mosaicism, and genetic background are all important factors in determining this variability. Men's phenotypes may be slightly more severe. However, Mutations in PKD1 or PKD2 reduce intracellular calcium, increase cyclic adenosine monophosphate (cAMP), activate protein kinase A, and increase the susceptibility of collecting duct main cells to the steady tonic impact of vasopressin. Calcium signalling disturbance along with increased cAMP signalling activate downstream signalling pathways that are responsible for poor tubulogenic, cell proliferation, increased fluid secretion, and interstitial inflammation. Additionally, Symptoms and signs include flank and stomach pain, hematuria, and hypertension. CT or ultrasonography used to make the diagnosis. Prior to renal failure, treatment is symptomatic, followed by dialysis or transplantation.
[395730]
Market Dynamics
As a result of a greater emphasis on early diagnosis, technological advances in diagnostic processes have lowered the number of undetected cases. As a result, the consistently expanding number of diagnosed autosomal dominant polycystic kidney disease cases provides the potential for companies to offer innovative medicines in the global autosomal dominant polycystic kidney disease therapeutics market. Furthermore, progress made in establishing the genetic etiology of autosomal dominant polycystic kidney disease, non-invasive monitoring, and forecasting disease progression will benefit disease management. Pre-symptomatic diagnosis and its application in the care and managing the patients contribute to the growth of the autosomal dominant polycystic kidney disease market. Moreover, the ADPKD pipeline is robust and active, with several therapies being developed at various stages, strengthening the autosomal dominant polycystic kidney disease market's growth. Additionally, the identification of biomarkers for the early detection of autosomal dominant polycystic kidney disease patients at high risk of advancement would aid in the improved patient management and the prevention of disease progression.
Market Ecosystem
The global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market has analyzed from three perspectives: drug class, distribution channel and region.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market by Drug Class
[4213113]
Based on drug classes, the global autosomal dominant polycystic kidney disease therapeutics market has been segmented into vasopressin antagonists, ace inhibitors, angiotensin II receptor blockers, and others. The vasopressin antagonist segment dominated the market during the forecast period. Treatments for autosomal dominant polycystic kidney disease (ADPKD) may reduce morbidity and death owing to disease-related complications, but they do not slow disease progression. Tolvaptan, a selective vasopressin V2 receptor antagonist, improves pain and delays the increase in kidney volume (a surrogate measure for disease progression) in ADPKD patients with maintained renal function.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market by Distribution Channel
Based on the distribution channels, the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market has segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment dominated the market during the forecast period. Hospitals pharmacy took the lead as they have more operating capital to invest in cutting-edge medical technologies. Hospitals hold the essential medical equipment to offer patients complete care because they are frequently multi-specialty centres.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market by Region
Geographically, the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is anticipated to dominate the market during forecast period, owing to high per capita income and rising awareness of the early identification of chronic renal illnesses as a result of educational improvement in the region's medical system. According to the World Bank data, the annual income of each individual in the United States increased to US$ 69,287.5 in 2021 from US$ 63,027.7 in 2020. Furthermore, inexpensive healthcare policies, extensive drug research and development, a major rise in the medical and healthcare industries, and drug accessibility are predicted to fuel the autosomal dominant polycystic kidney disease industry growth.
Extensive research and development on medication therapies to treat polycystic kidney disease by key businesses in Germany, Switzerland, and the United Kingdom is likely to drive the European market. Significant growth in the medical and healthcare industries in China, Japan, and Australia is expected to drive the Asia Pacific autosomal dominant polycystic kidney disease therapeutics market in the near future. Advancements in tests and diagnosis, rising per capita income, and drug availability are expected to boost the autosomal dominant polycystic kidney disease therapeutics market in the Middle East and Africa over the forecast period.
Competitive Landscape
Some of the prominent market players in the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market include:
To stay ahead of the competition, the market's major competitors are focusing on extending their geographical presence and investing in product development. The use of organic and inorganic methods by the companies aids the polycystic kidney disease treatment market is growing at a rapid pace.
Strategic Developments
Europe is the key growth region in the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market.
The growing special regulatory designations and technological innovations are the prime driving factors.
The global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market expected to clock US$ 2.76 billion by 2030.
The global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market is expected to witness a CAGR of 11% during the forecast period from 2022 to 2030.
Some of the prominent market players in the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market include Otsuka Pharmaceutical Co., Ltd., Regulus Therapeutics, Palladio Biosciences, Reata Pharmaceuticals, Inc., Galapagos NV, AceLink Therapeutics, Inc., Exelixis, Inc, XORTX Therapeutics Inc., Sanofi S.A., and Pano Therapeutics, Inc., among others.
*Insights on financial performance are subject to availability of the information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst